MYLK

Across TCGA pan-cancer cohorts, MYLK mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MYLK data layer compared with 23 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher MYLK mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MYLK expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

GBM, PDAC, and LUAD are the cancer types where MYLK mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Quartile	All	0.392	0.692	<.001	30	view →
PDAC	DFS	Median	III,IV	0.755	0.304	.003	14	view →
LUAD	DFS	Median	All	0.957	0.644	.006	7	view →
CCRCC	DFS	Median	III,IV	0.815	0.436	.011	6	view →
LSCC	DFS	Quartile	II,III,IV	0.546	0.933	.016	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MYLK–GBM (OS)

Open the GBM breakdown →